Related Experiment Video
Updated: Jul 4, 2025
09:12
A Mouse Model of Chronic Liver Fibrosis for the Study of Biliary Atresia
Published on: February 3, 2023
2.5K
CFHR1 involvement in bile duct carcinoma: Insights from a data mining study
Yan Liu1, Tianhao Shen2, Jianming Liu2
1Oncology Intervention Department, Putuo Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, 200062, China; Institute of Tumor Intervention, Putuo Hospital Shanghai University of Traditional Chinese Medicine, Shanghai, 20062, China.
Analytical Biochemistry
|January 29, 2024
Summary
Complement Factor H-Related Protein 1 (CFHR1) is upregulated in bile duct carcinoma (BDC), correlating with poor prognosis and immune cell infiltration. This suggests CFHR1 is a potential prognostic marker and therapeutic target for BDC.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Bile duct carcinoma (BDC), also known as cholangiocarcinoma, is a rare and aggressive cancer.
- Understanding the molecular mechanisms underlying BDC pathogenesis is crucial for developing effective therapeutic strategies.
Purpose of the Study:
- To investigate the role of Complement Factor H-Related Protein 1 (CFHR1) in bile duct carcinoma (BDC).
- To elucidate the mechanism of action of CFHR1 in BDC.
- To identify potential prognostic markers and therapeutic targets for BDC.
Main Methods:
- Survival receiver operating characteristic (ROC) curve analysis to assess CFHR1's prognostic value.
- STRING database for protein-protein interaction network analysis.
- Microenvironment Cell Populations counter algorithm for immune cell infiltration analysis.
- Experimental verification of CFHR1's biological function.
Main Results:
- CFHR1 was found to be upregulated in BDC tissues.
- CFHR1 expression correlated with clinicopathological parameters and indicated a poor prognosis.
- CFHR1 expression was associated with immune cell infiltration and immune cell markers in BDC (P < 0.05).
- 20 related differentially expressed genes (DEGs) were identified, with 8 downregulated and 12 upregulated.
Conclusions:
- CFHR1 may serve as a valuable prognostic marker for BDC.
- CFHR1 represents a potential therapeutic target for BDC.
- Further understanding of CFHR1's role can aid in improving BDC diagnosis and treatment.
